Sartorius has around €10 billion ($10.2 billion) firepower at its disposal but says it is interested in complementary technologies and innovation rather than just bulking up its market share. Like its rival bioprocess peers, Sartorius has been active in the mergers and acquisition space. The Germany-based firm has built up its product portfolio and biopharma services business through complementary M&A and is set to continue such a strategy going forward. In the firm’s first half 2022 conference call, CEO Joachim…